Ergotamine et caféine : interactions médicamenteuses

Ergotamine et caféine (Cafergot, Migergot), alcaloïde de l'ergot de seigle, présente 274 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 89 de niveau majeur, 129 de niveau modéré, 49 de niveau mineur et 7 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (89)

  • AdénosineantiarythmiqueMajeure

    Use of methylxanthines (e.g., caffeine, aminophylline and theophylline) is not recommended in patients who experience a seizures in association with adenosine injection ( 5.6 ) (notice Adénosine, Mises en garde et précautions)

  • AdrénalinesympathomimétiqueMajeure

    …hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result… (notice Adrénaline, Interactions médicamenteuses)

  • AlmotriptantriptanMajeure

    Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 ) (notice Almotriptan, Contre-indications)

  • AmiodaroneantiarythmiqueMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Amphétaminestimulant du SNCMajeure

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (notice Amphétamine, Contre-indications)

  • Amphétamine et dexamfétaminestimulant du SNCMajeure

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (notice Amphétamine et dexamfétamine, Contre-indications)

  • Aprépitantinhibiteur du CYP3A4Majeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Arformotérolagoniste bêta-adrénergiqueMajeure

    Excessive Use of Arformoterol Tartrate Inhalation Solution and Use with Other Long-Acting Beta2-Agonists Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Arformotérol, Mises en garde et précautions)

  • AtazanavirantirétroviralMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Azithromycineantibiotique macrolideMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Benzfétaminestimulant du SNCMajeure

    Benzphetamine Hydrochloride Tablets should not be used concomitantly with other CNS stimulants. (notice Benzfétamine, Contre-indications)

  • Budésonide et formotérolcorticoïdeMajeure

    Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Budésonide et formotérol, Mises en garde et précautions)

  • Bupivacaïneanesthésique localMajeure

    Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3)]. (notice Bupivacaïne, Mises en garde et précautions)

  • Bupivacaïne et adrénalineanesthésique localMajeure

    Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ] . (notice Bupivacaïne et adrénaline, Mises en garde et précautions)

  • CénobamateanticonvulsivantMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Chloroprocaïneanesthésique localMajeure

    Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (notice Chloroprocaïne, Mises en garde)

  • CiclosporineimmunosuppresseurMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Cimétidineantihistaminique H2Majeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • CiprofloxacinefluoroquinoloneMajeure

    Serious Adverse Reactions with Concomitant Theophylline Serious and fatal reactions have been reported in patients receiving concurrent administration of ciprofloxacin and theophylline. (notice Ciprofloxacine, Mises en garde et précautions)

  • Clarithromycineantibiotique macrolideMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Cocaïneanesthésique localMajeure

    WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (notice Cocaïne, Mise en garde encadrée)

  • DarunavirantirétroviralMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Darunavir et cobicistatantirétroviralMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Déférasiroxsupplément de ferMajeure

    Avoid the use of Exjade with CYP1A2 substrate theophylline. (notice Déférasirox, Interactions médicamenteuses)

  • Dexamfétaminestimulant du SNCMajeure

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ]. (notice Dexamfétamine, Contre-indications)

  • Dihydroergotaminealcaloïde de l'ergot de seigleMajeure

    Dihydroergotamine Mesylate Injection, USP, 5-HT 1 agonists (e.g., sumatriptan), ergotamine-containing or ergot-type medications or methysergide should not be used within 24 hours of each other. (notice Dihydroergotamine, Contre-indications)

  • Diltiazeminhibiteur calciqueMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • DronabinolcannabinoïdeMajeure

    Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (notice Dronabinol, Mises en garde et précautions)

  • DronédaroneantiarythmiqueMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • ÉfavirenzantirétroviralMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • ÉlétriptantriptanMajeure

    • Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1) ] . (notice Élétriptan, Contre-indications)

  • WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Érythromycineantibiotique macrolideMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • ÉvérolimusimmunosuppresseurMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Fidaxomicineantibiotique macrolideMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Fluconazoleantifongique azoléMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Fluticasone et salmétérolcorticoïdeMajeure

    Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Fluticasone et salmétérol, Mises en garde et précautions)

  • Formotérolagoniste bêta-adrénergiqueMajeure

    Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Formotérol, Mises en garde et précautions)

  • FosamprénavirantirétroviralMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Fosaprépitantinhibiteur du CYP3A4Majeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • FrovatriptantriptanMajeure

    Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1 , 7.2) ]. (notice Frovatriptan, Contre-indications)

  • Imatinibinhibiteur du CYP3A4Majeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Imipramineantidépresseur tricycliqueMajeure

    Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (notice Imipramine, Interactions médicamenteuses)

  • Ipratropium et salbutamolanticholinergiqueMajeure

    DO NOT EXCEED RECOMMENDED DOSE Fatalities have been reported in association with excessive use of inhaled products containing sympathomimetic amines and with the home use of nebulizers. (notice Ipratropium et salbutamol, Mises en garde)

  • IsoniazideantibiotiqueMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Itraconazoleantifongique azoléMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Ivacaftorinhibiteur du CYP3A4Majeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Kétaminedépresseur du SNCMajeure

    Theophylline or Aminophylline : Do not co-administer with KETALAR as concomitant use may lower the seizure threshold ( 7.1 ). (notice Kétamine, Interactions médicamenteuses)

  • Kétoconazoleantifongique azoléMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • LénacapavirantirétroviralMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Lévosalbutamolagoniste bêta-adrénergiqueMajeure

    Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (notice Lévosalbutamol, Mises en garde et précautions)

  • Lévothyroxine et liothyroninehormone thyroïdienneMajeure

    Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

  • Lidocaïne et adrénalineanesthésique localMajeure

    Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ]. (notice Lidocaïne et adrénaline, Mises en garde et précautions)

  • Liothyroninehormone thyroïdienneMajeure

    • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (notice Liothyronine, Mise en garde encadrée)

  • Lopinavir et ritonavirantirétroviralMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Mépivacaïneanesthésique localMajeure

    Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (notice Mépivacaïne, Mises en garde)

  • Méthamphétaminestimulant du SNCMajeure

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (notice Méthamphétamine, Contre-indications)

  • Mifépristoneinhibiteur du CYP3A4Majeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Mirabégronagoniste bêta-adrénergiqueMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • NaratriptantriptanMajeure

    …Ischemic bowel disease [see Warnings and Precautions (5.5)] Uncontrolled hypertension [see Warnings and Precautions (5.8)] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan tablets (angioedema… (notice Naratriptan, Contre-indications)

  • NéfazodoneantidépresseurMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Oxybate de sodiumdépresseur du SNCMajeure

    Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials ( 14 )]. (notice Oxybate de sodium, Mise en garde encadrée)

  • Palbociclibinhibiteur du CYP3A4Majeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • PentoxifyllineméthylxanthineMajeure

    CONTRAINDICATIONS Pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine. (notice Pentoxifylline, Contre-indications)

  • PérampanelanticonvulsivantMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Phendimétrazinestimulant du SNCMajeure

    …hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other anorectic agents or CNS stimulants • Known hypersensitivity or idiosyncratic reactions to sympathomimetics (notice Phendimétrazine, Contre-indications)

  • PhénelzineIMAOMajeure

    Excessive amounts of caffeine and chocolate may also cause hypertensive reactions. (notice Phénelzine, Contre-indications)

  • PimozideantipsychotiqueMajeure

    Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have been withdrawn from these drugs to determine whether or not the drugs, rather than Tourette’s Disorder, are responsible for the tics. (notice Pimozide, Contre-indications)

  • Posaconazoleantifongique azoléMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Ranolazinemédicament allongeant l'intervalle QTMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • RifampicineantibiotiqueMajeure

    Quinine Prevention or Management : Avoid concomitant use Decrease AUC by 75%-85% Telithromycin Decrease AUC by 86% Theophylline Decrease exposure by 20%-40% Effect of Other Drugs on Rifampin Concomitant antacid administration may reduce the absorption of rifampin. (notice Rifampicine, Interactions médicamenteuses)

  • RiociguatvasodilatateurMajeure

    Phosphodiesterase Inhibitors Concomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )]. (notice Riociguat, Contre-indications)

  • RitonavirantirétroviralMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • RizatriptantriptanMajeure

    Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (notice Rizatriptan, Contre-indications)

  • Salbutamolagoniste bêta-adrénergiqueMajeure

    Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (notice Salbutamol, Mises en garde et précautions)

  • Salmétérolagoniste bêta-adrénergiqueMajeure

    Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Salmétérol, Mises en garde et précautions)

  • SumatriptantriptanMajeure

    …Precautions (5.5)] • Ischemic bowel disease [see Warnings and Precautions (5.5)] • Uncontrolled hypertension [see Warnings and Precautions (5.8)] • Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine 1 (5-HT 1 ) agonist [see Drug Interactions (7.1,… (notice Sumatriptan, Contre-indications)

  • Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (notice Sumatriptan et naproxène, Contre-indications)

  • Suvorexantsédatif-hypnotiqueMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Terbutalineagoniste bêta-adrénergiqueMajeure

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (notice Terbutaline, Contre-indications)

  • Ticagrélorantiagrégant plaquettaireMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • TranylcypromineIMAOMajeure

    …hot dogs, breakfast sausage, and cooked sliced ham) Vegetables Broad bean pods (fava bean pods) All other vegetables Dairy Aged cheeses Processed cheeses, mozzarella, ricotta cheese, cottage cheese, and yogurt Beverages All varieties of tap beer and beers that have not been pasteurized so as to allow for ongoing fermentation and excessive amounts of caffeine. (notice Tranylcypromine, Interactions médicamenteuses)

  • Trinitrinedérivé nitréMajeure

    Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible. (notice Trinitrine, Interactions médicamenteuses)

  • Uméclidinium et vilantérolanticholinergiqueMajeure

    Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (notice Uméclidinium et vilantérol, Mises en garde et précautions)

  • Vérapamilinhibiteur calciqueMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • Voriconazoleantifongique azoléMajeure

    WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (notice Ergotamine et caféine, Mise en garde encadrée)

  • ZolmitriptantriptanMajeure

    …bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (notice Zolmitriptan, Contre-indications)

Interactions modérées (129)

  • AcébutololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Acétazolamideinhibiteur de l'anhydrase carboniqueModérée

    Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (notice Acétazolamide, Interactions médicamenteuses)

  • AclidiniumanticholinergiqueModérée

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (notice Aclidinium, Interactions médicamenteuses)

  • AdalimumabimmunosuppresseurModérée

    Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (notice Adalimumab, Interactions médicamenteuses)

  • AlbendazoleModérée

    Theophylline: Albendazole induces cytochrome P450 1A in human hepatoma cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment. (notice Albendazole, Interactions médicamenteuses)

  • Alogliptine et metformineinhibiteur de la DPP-4Modérée

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (notice Alogliptine et metformine, Interactions médicamenteuses)

  • AlprazolambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Alprazolam, Mises en garde et précautions)

  • Amitriptylineantidépresseur tricycliqueModérée

    When amitriptyline is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required. (notice Amitriptyline, Interactions médicamenteuses)

  • Articaïne et adrénalineanesthésique localModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • AténololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Aténolol et chlortalidonebêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • AzathioprineimmunosuppresseurModérée

    It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving IMURAN and xanthine oxidase inhibitors because both TPMT and XO inactivation pathways are affected (see CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections). (notice Azathioprine, Interactions médicamenteuses)

  • BétaxololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • BisoprololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Bisoprolol et hydrochlorothiazidebêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • BortézomibModérée

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (notice Bortézomib, Mises en garde et précautions)

  • Brimonidine et timololagoniste alpha-adrénergiqueModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (notice Bromphéniramine, pseudoéphédrine et dextrométhorphane, Interactions médicamenteuses)

  • BupropionantidépresseurModérée

    …medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse of prescription drugs such as CNS stimulants. (notice Bupropion, Mises en garde et précautions)

  • ButorphanolopioïdeModérée

    …Interactions It is not known if the effects of Butorphanol Tartrate Injection are altered by concomitant medications that affect hepatic metabolism of drugs (CYP 450 inhibitors or inducers) (e.g., erythromycin, theophylline, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed. (notice Butorphanol, Interactions médicamenteuses)

  • Cannabidiol (sur ordonnance)anticonvulsivantModérée

    Increases in exposure of certain CYP1A2 substrates (e.g., theophylline, tizanidine) may be observed when concomitantly used with EPIDIOLEX. (notice Cannabidiol (sur ordonnance), Interactions médicamenteuses)

  • CarvédilolbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • CétirizineantihistaminiqueModérée

    There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect [see Clinical Pharmacology ( 12.3 )]. (notice Cétirizine, Interactions médicamenteuses)

  • ChlordiazépoxidebenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Chlordiazépoxide, Mises en garde)

  • Chlordiazépoxide et clidiniumbenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Chlordiazépoxide et clidinium, Mises en garde)

  • CitalopramISRSModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (notice Citalopram, Mises en garde et précautions)

  • ClobazambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Clobazam, Mises en garde et précautions)

  • Clomipramineantidépresseur tricycliqueModérée

    Close supervision and careful adjustment of dosage are required when clomipramine hydrochloride capsules are administered with anticholinergic or sympathomimetic drugs. (notice Clomipramine, Interactions médicamenteuses)

  • ClonazépambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Clonazépam, Mises en garde)

  • ClorazépatebenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Clorazépate, Mises en garde)

  • Désipramineantidépresseur tricycliqueModérée

    Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs. (notice Désipramine, Interactions médicamenteuses)

  • Désogestrel et éthinylestradiolcontraceptif oralModérée

    Effects of Combined Hormonal Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Désogestrel et éthinylestradiol, Interactions médicamenteuses)

  • DesvenlafaxineIRSNaModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (notice Desvenlafaxine, Mises en garde et précautions)

  • DiazépambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Diazépam, Mises en garde)

  • Diclofénamideinhibiteur de l'anhydrase carboniqueModérée

    Drugs that Cause Hypokalemia The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3) ] . (notice Diclofénamide, Interactions médicamenteuses)

  • DicyclovérineanticholinergiqueModérée

    …drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (notice Dicyclovérine, Interactions médicamenteuses)

  • Digoxineglycoside digitaliqueModérée

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (notice Digoxine, Interactions médicamenteuses)

  • Dorzolamide et timololinhibiteur de l'anhydrase carboniqueModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • DoxapramModérée

    Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (notice Doxapram, Interactions médicamenteuses)

  • Drospirénone et éthinylestradiolcontraceptif oralModérée

    …studies, administration of a hormonal contraceptive containing EE did not lead to any increase or only to a weak increase in plasma concentrations of CYP3A4 substrates (e.g., midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase. (notice Drospirénone et éthinylestradiol, Interactions médicamenteuses)

  • DuloxétineIRSNaModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (notice Duloxétine, Mises en garde et précautions)

  • Dutastéride et tamsulosineinhibiteur de la 5-alpha-réductaseModérée

    Tamsulosin Dosage adjustments are not necessary when tamsulosin is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3) ]. (notice Dutastéride et tamsulosine, Interactions médicamenteuses)

  • ÉphédrinesympathomimétiqueModérée

    • Pr e ssor Effect with Concomitant Oxytocic Drugs : Pressor effect of sympathomimetic pressor amines is potentiated (5.1) (notice Éphédrine, Mises en garde et précautions)

  • EscitalopramISRSModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (notice Escitalopram, Mises en garde et précautions)

  • EsmololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • EstazolambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Estazolam, Mises en garde)

  • Effects of CHCs on Other Drugs CHCs containing ethinyl estradiol may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Étonogestrel et éthinylestradiol, Interactions médicamenteuses)

  • FluoxétineISRSModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. (notice Fluoxétine, Mises en garde et précautions)

  • FluvoxamineISRSModérée

    Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (notice Fluvoxamine, Mises en garde et précautions)

  • FosphénytoïneanticonvulsivantModérée

    John's wort may vary widely based on preparation. theophylline Drugs that may either increase or decrease phenytoin serum levels Antiepileptic drugs Phenobarbital, valproate sodium, valproic acid 7.2 Drugs Affected by Phenytoin or CEREBYX Table 7 includes commonly occurring drug interactions affected by phenytoin (the active metabolite of CEREBYX). (notice Fosphénytoïne, Interactions médicamenteuses)

  • Glimépiridesulfamide hypoglycémiantModérée

    …somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (notice Glimépiride, Interactions médicamenteuses)

  • Glipizidesulfamide hypoglycémiantModérée

    …olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (notice Glipizide, Interactions médicamenteuses)

  • Guanfacineagoniste alpha-adrénergiqueModérée

    In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine. (notice Guanfacine, Mises en garde et précautions)

  • InfliximabimmunosuppresseurModérée

    Upon initiation or discontinuation of RENFLEXIS in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (notice Infliximab, Interactions médicamenteuses)

  • Insuline asparteinsulineModérée

    …Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline asparte, Interactions médicamenteuses)

  • Insuline dégludecinsulineModérée

    …Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline dégludec, Interactions médicamenteuses)

  • Insuline détémirinsulineModérée

    …Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline détémir, Interactions médicamenteuses)

  • Insuline glargineinsulineModérée

    …Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline glargine, Interactions médicamenteuses)

  • Insuline lisproinsulineModérée

    …Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Insuline lispro, Interactions médicamenteuses)

  • LabétalolbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Lansoprazoleinhibiteur de la pompe à protons (IPP)Modérée

    Theophylline Clinical Impact: Increased clearance of theophylline [see Clinical Pharmacology (12.3) ] . (notice Lansoprazole, Interactions médicamenteuses)

  • LéflunomideimmunosuppresseurModérée

    In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (notice Léflunomide, Interactions médicamenteuses)

  • LévocétirizineantihistaminiqueModérée

    There was a small decrease (~16%) in the clearance of cetirizine caused by a 400 mg dose of theophylline. (notice Lévocétirizine, Interactions médicamenteuses)

  • LévofloxacinefluoroquinoloneModérée

    However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. (notice Lévofloxacine, Interactions médicamenteuses)

  • LévomilnacipranIRSNaModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (notice Lévomilnacipran, Mises en garde et précautions)

  • Lévonorgestrel et éthinylestradiolcontraceptif oralModérée

    Concomitant use with ethinyl estradiol-containing CHCs may increase systemic exposure of other drugs (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole). (notice Lévonorgestrel et éthinylestradiol, Interactions médicamenteuses)

  • Lévothyroxinehormone thyroïdienneModérée

    Sympathomimetics Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. (notice Lévothyroxine, Interactions médicamenteuses)

  • Lidocaïneanesthésique localModérée

    Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (notice Lidocaïne, Interactions médicamenteuses)

  • LinézolideantibiotiqueModérée

    …administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (notice Linézolide, Mises en garde et précautions)

  • Lisdexamfétaminestimulant du SNCModérée

    Additionally, in studies of another stimulant, there was slowing of the increase in height [see Adverse Reactions (6.1) ] . (notice Lisdexamfétamine, Mises en garde et précautions)

  • LorazépambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Lorazépam, Mises en garde et précautions)

  • MercaptopurineantimétaboliteModérée

    Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (notice Mercaptopurine, Interactions médicamenteuses)

  • MéthotrexateimmunosuppresseurModérée

    Effect of XATMEP on Other Drugs Theophylline Methotrexate may decrease the clearance of theophylline. (notice Méthotrexate, Interactions médicamenteuses)

  • Méthylergométrinealcaloïde de l'ergot de seigleModérée

    Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (notice Méthylergométrine, Interactions médicamenteuses)

  • Métolazonediurétique thiazidiqueModérée

    Sympathomimetics Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. (notice Métolazone, Interactions médicamenteuses)

  • MétoprololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • MexilétineantiarythmiqueModérée

    Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of mexiletine. (notice Mexilétine, Interactions médicamenteuses)

  • MilnacipranIRSNaModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (notice Milnacipran, Mises en garde et précautions)

  • MirtazapineantidépresseurModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (notice Mirtazapine, Mises en garde et précautions)

  • NadololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Naltrexone et bupropionantagoniste des opioïdesModérée

    …may cause hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to… (notice Naltrexone et bupropion, Mises en garde et précautions)

  • NatéglinideglinideModérée

    Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (notice Natéglinide, Interactions médicamenteuses)

  • NébivololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • NévirapineantirétroviralModérée

    Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (notice Névirapine, Interactions médicamenteuses)

  • Effects of Combined Hormonal Contraceptives on Other Drugs CHCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Norelgestromine et éthinylestradiol, Interactions médicamenteuses)

  • Norgestimate et éthinylestradiolcontraceptif oralModérée

    Effects of Combined Oral Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Norgestimate et éthinylestradiol, Interactions médicamenteuses)

  • Norgestrel et éthinylestradiolcontraceptif oralModérée

    Effects of Combined Oral Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other drugs (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Norgestrel et éthinylestradiol, Interactions médicamenteuses)

  • Nortriptylineantidépresseur tricycliqueModérée

    Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (notice Nortriptyline, Interactions médicamenteuses)

  • OfloxacinefluoroquinoloneModérée

    This may result in a prolonged half-life for some drugs that are also metabolized by this system (e.g., cyclosporine, theophylline/methylxanthines, warfarin) when coadministered with quinolones. (notice Ofloxacine, Interactions médicamenteuses)

  • Olanzapine et fluoxétineantipsychotiqueModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (notice Olanzapine et fluoxétine, Mises en garde et précautions)

  • OxazépambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Oxazépam, Mises en garde)

  • ParoxétineISRSModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (notice Paroxétine, Mises en garde et précautions)

  • Phenterminestimulant du SNCModérée

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (notice Phentermine, Mises en garde et précautions)

  • PhényléphrinedécongestionnantModérée

    Pressor Effect with Concomitant Oxytocic Drugs Oxytocic drugs potentiate the increasing blood pressure effect of sympathomimetic pressor amines including BIORPHEN [see Drug Interactions (7.1) ] , with the potential for hemorrhagic stroke. (notice Phényléphrine, Mises en garde et précautions)

  • PhénytoïneanticonvulsivantModérée

    John’s wort may vary widely based on preparation. , sucralfate, theophylline Drugs that may either increase or decrease phenytoin serum levels Antiepileptic drugs Phenobarbital, valproate sodium Valproate sodium and valproic acid are similar medications. (notice Phénytoïne, Interactions médicamenteuses)

  • PindololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Pioglitazone et glimépiridethiazolidinedioneModérée

    …somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (notice Pioglitazone et glimépiride, Interactions médicamenteuses)

  • Prilocaïne et adrénalineanesthésique localModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • PrimaquineantipaludiqueModérée

    Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (notice Primaquine, Interactions médicamenteuses)

  • PropranololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • PropylthiouracileantithyroïdienModérée

    Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. (notice Propylthiouracile, Interactions médicamenteuses)

  • Protriptylineantidépresseur tricycliqueModérée

    Drug Interactions When protriptyline is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required. (notice Protriptyline, Interactions médicamenteuses)

  • QuinineantipaludiqueModérée

    Theophylline or Aminophylline In 20 healthy subjects who received multiple doses of quinine sulfate (648 mg every 8 hours x 7 days) with a single 300 mg oral dose of theophylline, the quinine mean C max and AUC were increased by 13% and 14% respectively. (notice Quinine, Interactions médicamenteuses)

  • RasagilineIMAOModérée

    Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. (notice Rasagiline, Interactions médicamenteuses)

  • RifapentineantibiotiqueModérée

    …Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline,… (notice Rifapentine, Interactions médicamenteuses)

  • SélégilineIMAOModérée

    Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). (notice Sélégiline, Mises en garde et précautions)

  • SertralineISRSModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (notice Sertraline, Mises en garde et précautions)

  • SotalolbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • SucralfateModérée

    Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (notice Sucralfate, Interactions médicamenteuses)

  • Tadalafilinhibiteur de la PDE5Modérée

    When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed. (notice Tadalafil, Interactions médicamenteuses)

  • TamsulosinealphabloquantModérée

    Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (notice Tamsulosine, Interactions médicamenteuses)

  • TémazépambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Témazépam, Mises en garde)

  • TerbinafineantifongiqueModérée

    Terbinafine decreases the clearance of caffeine by 19%. (notice Terbinafine, Interactions médicamenteuses)

  • TériflunomideimmunosuppresseurModérée

    In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (notice Tériflunomide, Interactions médicamenteuses)

  • ThiamazoleantithyroïdienModérée

    Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. (notice Thiamazole, Interactions médicamenteuses)

  • TimololbêtabloquantModérée

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • TiotropiumanticholinergiqueModérée

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (notice Tiotropium, Interactions médicamenteuses)

  • TocilizumabimmunosuppresseurModérée

    Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (notice Tocilizumab, Interactions médicamenteuses)

  • TolcaponeModérée

    Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (notice Tolcapone, Interactions médicamenteuses)

  • TriazolambenzodiazépineModérée

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Triazolam, Mises en garde et précautions)

  • VaréniclineModérée

    • Effect of Smoking Cessation on Other Drugs: Pharmacokinetics or pharmacodynamics of certain drugs (e.g., theophylline, warfarin, insulin) may be altered, necessitating dose adjustment. (notice Varénicline, Interactions médicamenteuses)

  • VenlafaxineIRSNaModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (notice Venlafaxine, Mises en garde et précautions)

  • VilazodoneISRSModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (notice Vilazodone, Mises en garde et précautions)

  • VortioxétineantidépresseurModérée

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. (notice Vortioxétine, Mises en garde et précautions)

  • WarfarineanticoagulantModérée

    …metronidazole, miconazole, oxandrolone, sulfinpyrazone, tigecycline, voriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol,… (notice Warfarine, Interactions médicamenteuses)

  • Zafirlukastantagoniste des récepteurs des leucotriènesModérée

    Coadministration of zafirlukast (20 mg/day) or placebo at steady-state with a single dose of sustained release theophylline preparation (16 mg/kg) in 16 healthy boys and girls (6 through 11 years of age) resulted in no significant differences in the pharmacokinetic parameters of theophylline. (notice Zafirlukast, Précautions)

  • Zileutoninhibiteur du CYP1A2Modérée

    Zileuton increases theophylline levels. (notice Zileuton, Interactions médicamenteuses)

  • ZiprasidoneantipsychotiqueModérée

    The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (notice Ziprasidone, Mises en garde et précautions)

Mentions mineures (49)

  • AcarboseantidiabétiqueMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (notice Acarbose, Interactions médicamenteuses)

  • AmantadineanticholinergiqueMineure

    Drug Interactions Careful observation is required when amantadine hydrochloride is administered concurrently with central nervous system stimulants. (notice Amantadine, Interactions médicamenteuses)

  • Amfépramonestimulant du SNCMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • AminophyllineméthylxanthineMineure

    Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. (notice Aminophylline, Interactions médicamenteuses)

  • Anagrélidemédicament allongeant l'intervalle QTMineure

    CYP1A2 substrates: AGRYLIN demonstrates limited inhibitory activity towards CYP1A2 in vitro and may alter the exposure of concomitant CYP1A2 substrates (e.g., theophylline, fluvoxamine, ondansetron). (notice Anagrélide, Interactions médicamenteuses)

  • Ergot derivatives: dihydroergotamine ergotamine methylergonovine ↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine Concomitant administration with dihydroergotamine, ergotamine or methylergonovine is not recommended. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

  • Bromocriptineagoniste de la dopamineMineure

    There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (notice Bromocriptine, Interactions médicamenteuses)

  • CarbamazépineanticonvulsivantMineure

    Such drugs include the following: Aminophylline, c isplatin, doxorubicin, felbamate, phosphenytoin, methsuximide , phenobarbital, phenytoin, primidone, rifampin and theophylline. (notice Carbamazépine, Interactions médicamenteuses)

  • Carbidopa, lévodopa et entacaponemédicament dopaminergiqueMineure

    Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have been reported in some patients treated with ergot derived dopaminergic agents. (notice Carbidopa, lévodopa et entacapone, Mises en garde et précautions)

  • CidofovirantiviralMineure

    …Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine). (notice Cidofovir, Interactions médicamenteuses)

  • Clotrimazoleantifongique azoléMineure

    Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole. (notice Ergotamine et caféine, Mises en garde)

  • ClozapineantipsychotiqueMineure

    Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. (notice Clozapine, Interactions médicamenteuses)

  • Dapagliflozine et metformineinhibiteur du SGLT2Mineure

    These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Dapagliflozine et metformine, Interactions médicamenteuses)

  • DobutaminesympathomimétiqueMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • DroxidopasympathomimétiqueMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Empagliflozine et metformineinhibiteur du SGLT2Mineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Empagliflozine et metformine, Interactions médicamenteuses)

  • Glibenclamidesulfamide hypoglycémiantMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glibenclamide, Interactions médicamenteuses)

  • Glibenclamide et metforminesulfamide hypoglycémiantMineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Glibenclamide et metformine, Interactions médicamenteuses)

  • Glipizide et metforminesulfamide hypoglycémiantMineure

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glipizide et metformine, Précautions)

  • Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (notice Insuline rapide (humaine), Interactions médicamenteuses)

  • IpratropiumanticholinergiqueMineure

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

  • Isoprénalineagoniste bêta-adrénergiqueMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Linagliptine et metformineinhibiteur de la DPP-4Mineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Linagliptine et metformine, Interactions médicamenteuses)

  • Lithiummédicament sérotoninergiqueMineure

    Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (notice Lithium, Interactions médicamenteuses)

  • MetforminebiguanideMineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Metformine, Interactions médicamenteuses)

  • MétronidazoleantibiotiqueMineure

    Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole. (notice Ergotamine et caféine, Mises en garde)

  • Miconazoleantifongique azoléMineure

    Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (notice Miconazole, Interactions médicamenteuses)

  • Midodrineagoniste alpha-adrénergiqueMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • Modafinilstimulant du SNCMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • OxymétazolinedécongestionnantMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • PamplemousseAliments et boissonsMineure

    Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole. (notice Ergotamine et caféine, Mises en garde)

  • Pioglitazone et metforminethiazolidinedioneMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Pioglitazone et metformine, Interactions médicamenteuses)

  • Pramipexoleagoniste de la dopamineMineure

    Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in patients treated with ergot-derived dopaminergic agents. (notice Pramipexole, Mises en garde et précautions)

  • Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (notice Probénécide, Interactions médicamenteuses)

  • Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (notice Probénécide et colchicine, Interactions médicamenteuses)

  • PseudoéphédrinedécongestionnantMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • QuinidineantiarythmiqueMineure

    Conversely, the pharmacokinetics of quinidine are not significantly affected by caffeine, ciprofloxacin, digoxin, felodipine, omeprazole, or quinine . (notice Quinidine, Interactions médicamenteuses)

  • Rameltéonsédatif-hypnotiqueMineure

    In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (notice Rameltéon, Mises en garde et précautions)

  • RépaglinideglinideMineure

    …antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (notice Répaglinide, Interactions médicamenteuses)

  • Ropiniroleagoniste de la dopamineMineure

    Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. (notice Ropinirole, Mises en garde et précautions)

  • Ropivacaïneanesthésique localMineure

    Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. (notice Ropivacaïne, Interactions médicamenteuses)

  • Saxagliptine et metformineinhibiteur de la DPP-4Mineure

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Saxagliptine et metformine, Interactions médicamenteuses)

  • Sitagliptine et metformineinhibiteur de la DPP-4Mineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Sitagliptine et metformine, Interactions médicamenteuses)

  • Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole. (notice Ergotamine et caféine, Mises en garde)

  • Tabac et tabagismeTabac et cannabisMineure

    Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (notice Ergotamine et caféine, Interactions médicamenteuses)

  • ThéophyllineméthylxanthineMineure

    Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. (notice Théophylline, Interactions médicamenteuses)

  • TiagabineanticonvulsivantMineure

    In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (notice Tiagabine, Mises en garde)

  • Trimipramineantidépresseur tricycliqueMineure

    Therefore, particular care should be exercised when it is necessary to administer tricyclic antidepressants with sympathomimetic amines, local decongestants, local anesthetics containing epinephrine, atropine or drugs with an anticholinergic effect. (notice Trimipramine, Interactions médicamenteuses)

  • Vibégronagoniste bêta-adrénergiqueMineure

    Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. (notice Ergotamine et caféine, Interactions médicamenteuses)

Aucune interaction significative signalée (7)

  • AlosétronAucune interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (notice Alosétron, Interactions médicamenteuses)

  • DofétilideantiarythmiqueAucune interaction

    Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of dofetilide. (notice Dofétilide, Interactions médicamenteuses)

  • FamciclovirantiviralAucune interaction

    …Penciclovir No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine. (notice Famciclovir, Interactions médicamenteuses)

  • Finastérideinhibiteur de la 5-alpha-réductaseAucune interaction

    Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found. (notice Finastéride, Interactions médicamenteuses)

  • Montélukastantagoniste des récepteurs des leucotriènesAucune interaction

    No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology… (notice Montélukast, Interactions médicamenteuses)

  • Nizatidineantihistaminique H2Aucune interaction

    Drug Interactions No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. (notice Nizatidine, Interactions médicamenteuses)

  • OlanzapineantipsychotiqueAucune interaction

    Theophylline — Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites. (notice Olanzapine, Interactions médicamenteuses)

Vérifiez Ergotamine et caféine avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.